-The Telegraph New Delhi: Patients infected with the human immuno-deficiency virus (HIV) in the northeastern states have been unable to undergo a key test required to start anti-HIV Drugs for several weeks because of delays in procurement by government agencies, patient interest groups said today. The Indian Drug Users Forum said several government HIV-treatment centres across Manipur, Meghalaya, Nagaland and Tripura are facing a "complete stock-out" of biochemical reagents that measure levels...

-The Times of India NEW DELHI: In yet another twist to the Ranbaxy scandal, the drug regulatory authority of the UK government has issued a statement clarifying that they have found no evidence of any Ranbaxy product in the UK market having been "of unacceptable quality". Last month, WHO had issued a similar statement. It had said that there was no evidence of any of the Ranbaxy products being of unacceptable...

-The Economic Times Anshu Prakash is worried about what he calls "mischievous propaganda" by "some people" who he thinks are misleading reporters. The joint secretary at the ministry of health and family welfare starts off by flatly denying that the joint monitoring mission (JMM) set up by the World Health Organization (WHO) and the government of India (GoI) discussed the impending danger of a TB drugs stock-out in August 2012. "There was...

-The Hindu   Every day, more than 5,000 people develop tuberculosis; nearly three lakh children drop out of school owing to the disease and more than one lakh women are rejected by families in India. A middle-aged patient with a history of cough with blood-tinged sputum for three weeks duration consults a doctor. The physician puts forth a routine query whether anyone in his family suffers/suffered from tuberculosis? Annoyed, the patient responds: no...

-The Business Standard Why have Indian authorities woken up to the Ranbaxy case only now? The matter had been simmering for several years The Ranbaxy affair is one of the darkest chapters of India's business history. The company has admitted it fudged data so that it could launch its products in the United States. It has now paid $500 million as a penalty to settle the case. It is worse than Ramalinga...